AQST · Insider trading · 13F holders · Congress trades
Aquestive Therapeutics, Inc. (AQST)
Who is buying and selling AQST: company insiders on SEC Form 4, hedge funds and superinvestors on Form 13F, and members of Congress under the STOCK Act. Every figure links to the filing or page it comes from.
- 13F filers holding
- 10
- Insider buys, 90 days
- $0
- Insider sales, 90 days
- $379K
- Congress trades, 12 months
- 0
AQST at a glance
- Between Aug 1, 2026 and Oct 29, 2026, 2 AQST insiders filed 4 sales worth $379K on SEC Form 4, and no open-market purchases; 4 of the sales were pre-planned under Rule 10b5-1.
- 10 13F filers hold AQST among their 50 largest positions, worth $35.8M combined. The biggest bets by portfolio weight are Propel Bio Management, LLC (3.1%), Everstar Asset Management, LLC (1.2%) and Sio Capital Management, LLC (1.1%). In their latest 13Fs, 0 managers opened a new position and 3 added to one.
- No member of Congress has disclosed a trade in AQST.
- AQST last closed at $4.04 on Oct 29, 2026.
AQST insider trading
Between Aug 1, 2026 and Oct 29, 2026, 2 AQST insiders filed 4 sales worth $379K on SEC Form 4, and no open-market purchases; 4 of the sales were pre-planned under Rule 10b5-1.
| Filed | Insider | Role | Trade | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|---|
| Oct 16, 2026 | Barber Daniel | President and CEO, Director | Sale10b5-1 | 25,000 | $4.22 | $106K | SEC |
| Sep 16, 2026 | Barber Daniel | President and CEO, Director | Sale10b5-1 | 25,000 | $4.82 | $120K | SEC |
| Sep 11, 2026 | Korczynski Sherry | Chief Commercial Officer | Sale10b5-1 | 8,750 | $5.22 | $46K | SEC |
| Aug 18, 2026 | Barber Daniel | President and CEO, Director | Sale10b5-1 | 25,000 | $4.29 | $107K | SEC |
Who owns AQST? Hedge funds and superinvestors
10 13F filers hold AQST among their 50 largest positions, worth $35.8M combined. The biggest bets by portfolio weight are Propel Bio Management, LLC (3.1%), Everstar Asset Management, LLC (1.2%) and Sio Capital Management, LLC (1.1%). In their latest 13Fs, 0 managers opened a new position and 3 added to one.
| Manager | % of portfolio | Value | Shares | Last quarter | 13F |
|---|---|---|---|---|---|
| Samsara Biocapital, LLCHedge fund | 0.9% | $10.4M | 2,500,000 | +0.0% shares | Q2 2026 |
| Sio Capital Management, LLCHedge fund | 1.1% | $6.2M | 1,486,175 | -22.7% shares | Q2 2026 |
| Propel Bio Management, LLCHedge fund | 3.1% | $6.0M | 1,442,397 | +102.9% shares | Q2 2026 |
| Blue Owl Capital Holdings LPHedge fund | 0.6% | $3.9M | 942,932 | -30.0% shares | Q2 2026 |
| DAFNA Capital Management LLCHedge fund | 0.5% | $2.7M | 645,915 | +75.3% shares | Q2 2026 |
| Everstar Asset Management, LLCWealth manager | 1.2% | $2.5M | 611,943 | +10.6% shares | Q2 2026 |
| Bracebridge Capital, LLCHedge fund | 0.4% | $1.9M | 459,216 | +0.0% shares | Q2 2026 |
| Rosalind Advisors, Inc.Investment manager | 0.4% | $1.0M | 250,000 | +0.0% shares | Q2 2026 |
| Latash Investments, LLCInstitutional asset manager | 0.7% | $1.0M | 243,134 | +0.0% shares | Q2 2026 |
| Adirondack Capital Advisors, LLCWealth manager | 0.0% | $56K | 12,000 | +0.0% shares | Q3 2026 |
Each manager counts with its latest 13F (Q3 2026: 1, Q2 2026: 9). Screen AQST in the grand portfolio →
AQST stock trades by members of Congress
No member of Congress has disclosed a trade in AQST.
AQST questions and answers
Are insiders buying AQST stock?
Between Aug 1, 2026 and Oct 29, 2026, 2 AQST insiders filed 4 sales worth $379K on SEC Form 4, and no open-market purchases; 4 of the sales were pre-planned under Rule 10b5-1.
Which hedge funds own AQST?
10 13F filers hold AQST among their 50 largest positions, worth $35.8M combined. The biggest bets by portfolio weight are Propel Bio Management, LLC (3.1%), Everstar Asset Management, LLC (1.2%) and Sio Capital Management, LLC (1.1%). In their latest 13Fs, 0 managers opened a new position and 3 added to one.
Has Congress traded AQST?
No member of Congress has disclosed a trade in AQST.
Who is the largest holder of AQST?
Among 13F filers, Samsara Biocapital, LLC reports the largest AQST position, $10.4M (2,500,000 shares) in its Q2 2026 13F. The biggest bet by portfolio weight is Propel Bio Management, LLC's: 3.1% of its portfolio.
Cite or share this
Free to use with a link back. The data updates every filing day.